Black Titan (BTTC) versus Its Rivals Critical Comparison

Black Titan (NASDAQ:BTTC) is one of 48 public companies in the “Services – Computer Programming And Data Processing” industry, but how does it contrast to its peers? We will compare Black Titan to related companies based on the strength of its risk, analyst recommendations, earnings, profitability, valuation, dividends and institutional ownership.

Institutional and Insider Ownership

57.9% of shares of all “Services – Computer Programming And Data Processing” companies are owned by institutional investors. 53.7% of Black Titan shares are owned by company insiders. Comparatively, 20.6% of shares of all “Services – Computer Programming And Data Processing” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Black Titan and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Titan	1	0	0	0	1.00
Black Titan Competitors	98	200	218	14	2.28

As a group, “Services – Computer Programming And Data Processing” companies have a potential upside of 127.88%. Given Black Titan’s peers stronger consensus rating and higher probable upside, analysts plainly believe Black Titan has less favorable growth aspects than its peers.

Profitability

This table compares Black Titan and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Black Titan	N/A	-108.60%	-95.64%
Black Titan Competitors	-61.92%	-918.60%	-67.81%

Volatility and Risk

Black Titan has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Black Titan’s peers have a beta of 0.54, suggesting that their average share price is 46% less volatile than the S&P 500.

Valuation & Earnings

This table compares Black Titan and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Black Titan	$180,000.00	-$4.71 million	-0.55
Black Titan Competitors	$240.32 million	-$55.65 million	-10.70

Black Titan’s peers have higher revenue, but lower earnings than Black Titan. Black Titan is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

Black Titan peers beat Black Titan on 7 of the 13 factors compared.

About Black Titan

Titan Pharmaceuticals, Inc. is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.